Articles tagged "Viral therapy"

2017 American Transplant Congress
A Single Center's Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving an HCV Positive Kidney.
N. Kapila,¹ B. Zervos,² B. Ismail,¹ G. Schnickel,² J. Rivas,² D. Reino,² N. Agrawal,² A. Tzakis.²
¹Gastroenterology/Hepatology, Cleveland Clinic, Weston, FL; ²Transplant, Cleveland Clinic, Weston, FL
Background: Nearly 8% of patients in the U.S. undergoing hemodialysis are Hepatitis C (HCV) positive. There is a survival benefit in HCV positive patients who…
2017 American Transplant Congress
Mutations in Influenza A Virus and Clinical Implications in Transplant Recipients.
V. Ferreira,¹ A. Humar,¹ E. Cordero,² E. Blumberg,³ S. Husain,¹ J. Kalpoe,⁴ M. Multicenter Influenza Group, D. Kumar.¹
¹UHN, Toronto, Canada; ²REIPI, Seville, Spain; ³UPenn, Philadelphia; ⁴LUMC, Leiden, Netherlands
Background: Organ and hematopoietic stem cell transplant (HSCT) recipients are predisposed to complications of influenza infection and as such may constitute an important source of…
2017 American Transplant Congress
Hepatitis E Virus-Associated Cryoglobulinemia in Solid-Organ-Transplant Recipients: A Prospective Study.
O. Marion,¹ F. Abravanel,² L. Esposito,¹ S. Lhomme,² A. Del Bello,¹ J. Izopet,² N. Kamar.¹
¹Nephrology and Organ Transplant Unit, CHU Rangueil, Toulouse, France; ²Laboratory of Virology, CHU Purpan, Toulouse, France
Hepatitis E virus (HEV) is responsible for acute and chronic autochthonous hepatitis in developed countries, particularly in Western Europe. Conversely to hepatitis B or C,…
2017 American Transplant Congress
Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Solid Organ Transplant Recipients: A Phase 2 Study.
M. Pereira,¹ F. Silveira,² G. Papanicolaou,³ A. Langston,⁴ R. Avery,⁵ A. Wijatyk,⁶ J. Wu,⁶ M. Boeckh,⁷ F. Marty,⁸ S. Villano.⁹
¹Columbia University Medical Center, New York, NY; ²University of Pittsburgh Medical Center, Pittsburgh, PA; ³Memorial Sloan Kettering Cancer Center, New York, NY; ⁴Winship Cancer Institute, Atlanta, GA; ⁵Johns Hopkins University, Baltimore, MD; ⁶Shire, Lexington, MA; ⁷Fred Hutchinson Cancer Research Center, Seattle, WA; ⁸Brigham and Women's Hospital, Boston, MA; ⁹Shire (At Time of Study), Wayne, PA
Study NCT01611974 assessed safety, tolerability, and antiviral activity of maribavir (MBV) for treatment of resistant or refractory (R/R) CMV infections among transplant recipients. Those aged…
2017 American Transplant Congress
Low Dose Valganciclovir for CMV Prophylaxis in the First Year of Kidney Transplantation.
P. Klem,¹ L. Al-Omar,² J. Cooper,² S. Davis,² J. Gralla,² D. Choe,¹ A. Wiseman.²
¹Pharmacy, University of Colorado, Aurora, CO; ²Nephrology, University of Colorado, Aurora
Valganciclovir (VGC) is the standard antiviral agent used for the prevention of CMV diseases in moderate and high risk renal transplant recipients, yet the optimal…
2017 American Transplant Congress
Subclinical Rejections in Kidney Transplant Recipients Treated with Direct Acting Antiviral Agents for Hepatitis C Treatment within 1 Year of Transplant.
T. Rege,¹ K. Hatahet,¹ A. Gillespie,¹ M. Ghanta,¹ I. Lee,¹ K. Qureshi,¹ K. Lau,² S. Karhadkar,² A. DiCarlo,² S. Constantinescu,¹ S. Rao.¹
¹Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA; ²Surgery, Temple University, Philadelphia, PA
Direct acting antiviral agents (DAA) have revolutionized the management of Hepatitis C virus (HCV) positive kidney transplant recipients (KTR). The optimal timing of DAA therapy…
2017 American Transplant Congress
Kidney Transplant Allocation with CMV Matching Reduces CMV Infection and Related Costs.
J. Lockridge,¹ E. Langewisch,² D. Basuli,¹ A. Olyaei,³ C. Shaut,⁴ D. Norman.¹
¹Division of Nephrology, Department of Medicine, Oregon Health and Science University, Portland, OR; ²Nephrology, University of Nebraska, Omaha, NE; ³Pharmacy, Oregon Health and Sciences University, Portland, OR; ⁴Immunogenetics and Transplant, Oregon Health and Sciences University, Portland, OR
Cytomegalovirus (CMV) infection is a major cause of morbidity, mortality, and shortened graft survival in kidney transplant recipients. Efforts to prevent CMV infection have traditionally…
2017 American Transplant Congress
Kidney Allocation Using CMV Matching Optimizes Low and High Risk Profiles for Prevention of CMV Infection in Kidney Transplant Recipients.
J. Lockridge,¹ E. Langewisch,² D. Basuli,¹ A. Olyaei,³ C. Shaut,⁴ D. Norman.¹
¹Division of Nephrology, Department of Medicine, Oregon Health and Science University, Portland, OR; ²Nephrology, University of Nebraska, Omaha, NE; ³Pharmacy, Oregon Health and Sciences University, Portland, OR; ⁴Immunogenetics and Transplant, Oregon Health and Sciences University, Portland, OR
Cytomegalovirus (CMV) confers a major impact on morbidity, mortality, and graft survival in kidney transplant recipients. Efforts to prevent CMV disease and infection have traditionally…
2017 American Transplant Congress
Impact of Everolimus Added to a De Novo Belatacept Regimen on the Risk of BK Viremia After Kidney Transplant.
C. Larsen,¹ M. Alseiari,² S. Chandran,² F. Vincenti,² D. Wojciechowski.¹
¹Division of Nephrology, Massachusetts General Hospital, Boston, MA; ²Division of Nephrology, UCSF, San Francisco, CA
IntroductionBK viremia is a common complication following kidney transplantation. In vitro data suggest that inhibition of the mTOR–SP6-kinase pathway prevents expression of early viral genes…
2017 American Transplant Congress
Utility of “High-Dose” Ganciclovir in High Viral Load CMV Infection in Transplant Recipients.
M. Alfares, R. Avery, N. Turki, K. Alfares, S. Mehta, R. Boger, A. Valsamakis.
Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Pediatric Infectious Disease, Johns Hopkins, Baltimore, MD; Pathology, Johns Hopkins, Baltimore, MD
Background: High-dose ganciclovir (GCV) is often used for treatment of high viral load CMV, but few data exist on virologic outcomes and risk of neutropenia.…

« Previous Page
1
…
8
9
10
11
12
…
14
Next Page »